ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.44
-0.52%
US Tech 100
21,191.20
0.62%
S&P 500
6,051.09
0.00%
US Dollar vs CAD
1.42365
-0.01%
Bitcoin
101,753.04
0.29%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Innate Pharma SA (IPHA)

  7. Innate Pharma SA (IPHA) News

IPHA

Innate Pharma (IPHA)

Innate Pharma SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPHA
DateTimeSourceHeadlineSymbolCompany
12/09/20245:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
12/09/202412:00AMBusiness WireInnate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanésNASDAQ:IPHAInnate Pharma SA
12/09/202412:00AMBusiness WireInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell LymphomaNASDAQ:IPHAInnate Pharma SA
12/06/20245:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
12/06/202412:00AMBusiness WireInnate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaireNASDAQ:IPHAInnate Pharma SA
12/06/202412:00AMBusiness WireInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular LymphomaNASDAQ:IPHAInnate Pharma SA
12/03/20245:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
12/03/202412:00AMBusiness WireInnate Pharma partage les présentations sélectionnées pour le congrès annuel de l’ASH 2024NASDAQ:IPHAInnate Pharma SA
12/03/202412:00AMBusiness WireInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
11/20/20245:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/20/202412:00AMBusiness WireInnate Pharma Releases Its 2025 Financial CalendarNASDAQ:IPHAInnate Pharma SA
11/20/202412:00AMBusiness WireInnate Pharma publie son calendrier financier pour 2025NASDAQ:IPHAInnate Pharma SA
11/19/20245:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/19/202412:00AMBusiness WireInnate Pharma annonce une publication dans la revue Science Immunology mettant en avant le NK cell engager ANKET® de nouvelle génération IPH6501NASDAQ:IPHAInnate Pharma SA
11/19/202412:00AMBusiness WireInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501NASDAQ:IPHAInnate Pharma SA
11/13/20245:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/13/202412:00AMBusiness WireInnate Pharma présente ses résultats financiers au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
11/13/202412:00AMBusiness WireInnate Pharma Reports Third Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
11/08/20245:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/08/202412:00AMBusiness WireInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
11/08/202412:00AMBusiness WireInnate Pharma annonce les présentations de données de son portefeuille innovant en oncologie sélectionnées pour le congrès annuel du SITC 2024NASDAQ:IPHAInnate Pharma SA
11/07/202412:00AMBusiness WireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business UpdatesNASDAQ:IPHAInnate Pharma SA
11/07/202412:00AMBusiness WireInnate Pharma organise une conférence téléphonique pour ses résultats financiers et l’avancée de son portefeuille au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
10/29/20241:00AMBusiness WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
10/29/20241:00AMBusiness WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
10/14/202412:00AMBusiness WireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive BoardNASDAQ:IPHAInnate Pharma SA
10/14/202412:00AMBusiness WireJonathan Dickinson est nommé Président du Directoire d’Innate PharmaNASDAQ:IPHAInnate Pharma SA
09/30/202412:00AMBusiness WireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024NASDAQ:IPHAInnate Pharma SA
09/30/202412:00AMBusiness WireInnate Pharma co-organise un symposium scientifique en présence d’experts de l’Immunotherapie à New York le 3 octobre 2024NASDAQ:IPHAInnate Pharma SA
09/23/20245:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
 Showing the most relevant articles for your search:NASDAQ:IPHA

Your Recent History

LSE
TUNG
Tungsten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved